Literature DB >> 2587936

Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis.

G T Westermark1, K Sletten, P Westermark.   

Abstract

Amyloid protein AA consists of several subspecies which mainly arise through proteolytic cleavage at various sites of the precursor, serum protein AA. The most common protein AA subspecies (the protein AA prototype) contains 76 amino-acid residues. In previous studies we have shown that distinctive patterns of amyloid infiltration occur in AA-amyloidosis. The amyloid in different patterns of infiltration seems to consist of distinctive protein AA subspecies. In the present study we have analysed protein AA in three patients with a form of AA-amyloidosis with heavy vascular infiltration and show that the amyloid fibrils contain two groups of protein AA subspecies. One, quantitatively predominating, group contains large subspecies of up to 94 amino-acid residues and a second group of protein AA-molecules contains around 50 amino-acid residues. The AA molecules lack the N-terminal arginine residue. It is concluded that AA-amyloidosis with massive vascular infiltration is a distinctive subform with typical clinical and histological appearance and with fibrils containing characteristic protein AA subspecies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2587936     DOI: 10.1111/j.1365-3083.1989.tb02468.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  14 in total

1.  Influence of the carboxy terminus of serum amyloid A on protein oligomerization, misfolding, and fibril formation.

Authors:  Sanket Patke; Ronak Maheshwari; Jeffrey Litt; Saipraveen Srinivasan; J Javier Aguilera; Wilfredo Colón; Ravi S Kane
Journal:  Biochemistry       Date:  2012-03-26       Impact factor: 3.162

2.  AA-amyloidosis. Tissue component-specific association of various protein AA subspecies and evidence of a fourth SAA gene product.

Authors:  G T Westermark; K Sletten; A Grubb; P Westermark
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

3.  Systemic AA amyloidosis in the red fox (Vulpes vulpes).

Authors:  Anna Rising; Ella Cederlund; Carina Palmberg; Henrik Uhlhorn; Stefan Gaunitz; Kerstin Nordling; Erik Ågren; Elisabet Ihse; Gunilla T Westermark; Lars Tjernberg; Hans Jörnvall; Jan Johansson; Per Westermark
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

4.  Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation.

Authors:  C Röcken; R Menard; F Bühling; S Vöckler; J Raynes; B Stix; S Krüger; A Roessner; T Kähne
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

5.  Pulmonary vascular amyloidosis in aged dogs. A new form of spontaneously occurring amyloidosis derived from apolipoprotein AI.

Authors:  K H Johnson; K Sletten; D W Hayden; T D O'Brien; K E Roertgen; P Westermark
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

6.  Cleavage, Downregulation, and Aggregation of Serum Amyloid A.

Authors:  Wenhua Wang; Prabir Khatua; Ulrich H E Hansmann
Journal:  J Phys Chem B       Date:  2020-01-30       Impact factor: 2.991

Review 7.  The amyloid state of proteins in human diseases.

Authors:  David Eisenberg; Mathias Jucker
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

8.  Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis.

Authors:  Elisabet Ihse; Ole B Suhr; Ulf Hellman; Per Westermark
Journal:  J Mol Med (Berl)       Date:  2010-11-25       Impact factor: 4.599

9.  Influence of C-terminal truncation of murine Serum amyloid A on fibril structure.

Authors:  Matthies Rennegarbe; Inga Lenter; Angelika Schierhorn; Romy Sawilla; Christian Haupt
Journal:  Sci Rep       Date:  2017-07-21       Impact factor: 4.379

10.  AA-amyloidosis can be transferred by peripheral blood monocytes.

Authors:  Jana Sponarova; Sofia N Nyström; Gunilla T Westermark
Journal:  PLoS One       Date:  2008-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.